Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
出版年份 2021 全文链接
标题
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
作者
关键词
Health-related quality of life, CDK4/6 inhibitor, Palbociclib, Endocrine therapy, Hormone receptor–positive metastatic breast cancer
出版物
EUROPEAN JOURNAL OF CANCER
Volume 156, Issue -, Pages 70-82
出版商
Elsevier BV
发表日期
2021-08-20
DOI
10.1016/j.ejca.2021.07.004
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL
- (2020) M. Martin et al. ANNALS OF ONCOLOGY
- Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life
- (2019) Jamie M. Jacobs et al. Journal of the National Comprehensive Cancer Network
- Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
- (2019) Bingnan Zhang et al. BREAST CANCER RESEARCH AND TREATMENT
- Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
- (2019) Mario Giuliano et al. LANCET ONCOLOGY
- Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
- (2019) Yeon Hee Park et al. LANCET ONCOLOGY
- Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
- (2018) H S Rugo et al. ANNALS OF ONCOLOGY
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries
- (2018) Mathieu F. Janssen et al. PHARMACOECONOMICS
- Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
- (2016) N. Harbeck et al. ANNALS OF ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life
- (2016) Sun Young Rha et al. SUPPORTIVE CARE IN CANCER
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer
- (2014) Fabrice André et al. CURRENT MEDICAL RESEARCH AND OPINION
- The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2−negative metastatic breast cancer: experience from the patient perspective
- (2014) Shaloo Gupta et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
- (2012) K. Cocks et al. EUROPEAN JOURNAL OF CANCER
- Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets
- (2012) Ben van Hout et al. VALUE IN HEALTH
- Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
- (2010) C. Zielinski et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started